Contrasting Ocata Therapeutics (OCAT) & Its Rivals

Ocata Therapeutics (NASDAQ: OCAT) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Ocata Therapeutics to related companies based on the strength of its earnings, valuation, profitability, risk, dividends, institutional ownership and analyst recommendations.

Analyst Ratings

This is a summary of current ratings for Ocata Therapeutics and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocata Therapeutics 0 0 0 0 N/A
Ocata Therapeutics Competitors 1218 3585 12108 251 2.66

As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.63%.


This table compares Ocata Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ocata Therapeutics -4,564.66% -103.02% -46.18%
Ocata Therapeutics Competitors -5,585.47% -160.76% -35.81%

Insider & Institutional Ownership

48.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.3% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Ocata Therapeutics and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ocata Therapeutics N/A N/A N/A
Ocata Therapeutics Competitors $293.65 million $35.70 million 70.85

Ocata Therapeutics’ rivals have higher revenue and earnings than Ocata Therapeutics. Ocata Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


Ocata Therapeutics rivals beat Ocata Therapeutics on 5 of the 7 factors compared.

About Ocata Therapeutics

Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Receive News & Ratings for Ocata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocata Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply